MMP9 and myocardial infarction: Targeting MMP9 with such agents could therefore not only modulate ECM degradation but also distinctly impact the MMP9-dependent functions of these key infiltrating immune cells, offering a refined strategy for mitigating adverse cardiac remodeling in MI.